Article

Mechanisms of allergen-specific desensitization

Cytos Biotechnology AG, Zurich-Schlieren, Switzerland.
The Journal of allergy and clinical immunology (Impact Factor: 11.25). 08/2010; 126(2):375-83. DOI: 10.1016/j.jaci.2010.05.040
Source: PubMed

ABSTRACT Allergen-specific desensitization (SIT) is the most effective therapy for allergies. Although allergen-specific antibodies have an important role in the process, mechanisms of IgG-mediated inhibition of allergic reactions are not well defined.
We investigated mechanisms by which SIT-induced allergen-specific IgGs inhibit allergic reactions.
We generated mAbs that recognize 3 nonoverlapping epitopes of the major cat allergen Fel d 1. Each of the mAbs was produced as an IgE and different IgG isotype.
IgEs against 2 nonoverlapping epitopes on Fel d 1 are necessary and sufficient to sensitize mast cells for maximal FcepsilonRI signaling and degranulation on exposure to monomeric Fel d 1. IgE antibodies of a third specificity did not further increase mast cell degranulation, indicating that formation of large FcepsilonRI clusters are not required to induce maximal activation of mast cells. A single IgG that was specific for an epitope different from those recognized by the IgEs was a potent inhibitor of Fel d 1-mediated mast cell activation in vitro and in vivo. This inhibition required Fcgamma receptor-IIB. In human beings, IgGs of a single specificity were able to block degranulation of basophils from individuals with cat allergy. The inhibitory potential of these antibodies increased when larger allergen-IgG complexes were formed.
These data reconcile conflicting theories in the literature and might explain the reason IgE levels do not necessarily decrease during therapy, despite clinical efficacy. These findings have important implications for vaccine design.

1 Follower
 · 
144 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: An application of structural modeling and automated reasoning as an intelligent software development environment for concurrent programs is presented. This application, using an integration of software reuse and theorem-proving methods, synthesizes an absolutely correct program and increases software productivity. The concurrent programs are described by a Prolog-based concurrent object-oriented language called MENDEL/87. The functional part of the reusable component is generated by structural modeling, and the synchronization part is synthesized from temporal-logic specifications by the use of an automated-reasoning mechanism. A description is also given of the MENDELS ZONE, implemented on a Prolog machine, which is the working base of the method
    System Sciences, 1989. Vol.II: Software Track, Proceedings of the Twenty-Second Annual Hawaii International Conference on; 02/1989
  • [Show abstract] [Hide abstract]
    ABSTRACT: We present an extension of the recently introduced hierarchical least mean square (HLMS) algorithm. The original algorithm suffers from two major drawbacks, namely the incapability to converge for every unknown channel and the dramatic deterioration of its performance as the number of levels increases significantly. To be able to cope with these, a novel global gradient descent algorithm is proposed. This algorithm converges for every class of unknown filters and it exhibits faster convergence than HLMS in any case.
    Digital Signal Processing, 2002. DSP 2002. 2002 14th International Conference on; 02/2002
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Apis mellifera L. bee venom is the most studied hymenoptera allergen, but many aspects of its action on human basophils remain unclear. Allergologists seek evidence of the effectiveness of bee venom immunotherapy as this approach is the chosen treatment for systemic allergic reactions. The effect of bee venom on human basophils in vitro has not been studied in detail for many reasons, including the paucity of basophils in peripheral blood, inter-individual basophil response variability, and the reliability and predictability of basophil activation tests. We conducted a brief preliminary survey of the effect of Apis bee venom on healthy asymptomatic (non-allergic) subjects. A dose of an aqueous commercial extract of Apis bee venom as high as 10 µg/mL activated resting basophils (CD63=+80-90%, CD203c=+30%), while it inhibited the expression of CD63 (-50%) following basophil stimulation by the soluble agonists formyl-Met-Leu-Phe or anti-IgE. The activation of resting basophils appeared to be dose-related. Only when basophils were activated with an IgE-mediated agonist, did bee venom extract exhibit a possible priming mechanism at the lowest doses used only via CD63, while it was ineffective via CD203c. Autocrine interleukin-3 may play a role in the observed biphasic behavior.
    Allergy, asthma & immunology research 01/2011; 3(1):58-61. DOI:10.4168/aair.2011.3.1.58 · 3.08 Impact Factor